Delivery Order SPE2DB22D3004-SPE2DB25FSC62
- Not listed
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order valued at $22,877.40 to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injections. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical, designated SPE2DX and valued at $999,999,999. The delivery location is...
- The Defense Logistics Agency awarded a $14,455.29 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injections. This firm fixed-price contract, with an ultimate completion date of August 5, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $17,506.81 on August 20, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectable medication, with final completion scheduled for August 21, 2025. This is a firm fixed-price delivery order issued under a non-set-aside competitive procurement, with performance to be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $15,251.60 on August 15, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections. The contract, designated as a firm fixed price delivery order with an ultimate completion date of August 18, 2025, represents a non-competitive set-aside award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under the...
- The Defense Logistics Agency awarded a $26,993.06 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections, with an ultimate completion date of July 21, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order is a child contract issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $7,509.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections on August 19, 2025, with ultimate completion scheduled for August 20, 2025. This competitive award, placed under no set-aside designation, represents a child delivery order issued against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor agreement...
- The Defense Logistics Agency awarded a delivery order valued at $2,287.74 to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections. This is a firm fixed-price delivery order with no set-aside designation, demonstrating competitive award status. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 6, 2025. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injections on August 21, 2025, with a ceiling value of $6,243.72 and a completion date of August 22, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed price terms and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $11,924.08 to AmerisourceBergen Drug Corp for the supply of Zepbound 15 mg/0.5 ml pen injections on August 25, 2025, with an ultimate completion date of August 26, 2025. This firm fixed price contract, awarded without set-aside designation through competitive procurement, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $1,143.87 firm fixed-price delivery order on July 22, 2025, for Zepbound 15 mg/0.5 ml pen injections. This is a competitively awarded, non-set-aside contract with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and an ultimate completion date of July 23, 2025. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB25FSC62Delivery Order
The Defense Logistics Agency awarded a $9,847.98 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The delivery order is non-competitive and carries an ultimate completion date of August 22, 2025. Performance will be executed from AmerisourceBergen's Conshohocken, Pennsylvania location, where the company maintains its corporate office. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, fulfills this order as part of its comprehensive pharmaceutical support role for the Defense Health Agency and broader military healthcare systems. The contract supports the DLA's medical supply chain operations, which leverage AmerisourceBergen's extensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. Zepbound, a diabetes medication, aligns with AmerisourceBergen's demonstrated capability in supplying endocrinology treatments to federal healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.8k | 8/21/25 |